{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:33:13Z","timestamp":1770813193140,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.bjid.2017.10.009","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T13:35:36Z","timestamp":1518874536000},"page":"79-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder"],"prefix":"10.1016","volume":"22","author":[{"given":"Jose Abra\u00e3o","family":"Carneiro Neto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvane Braga","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria Orge","family":"Orge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davi","family":"Tanajura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Passos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassius Jos\u00e9","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosana","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udio Galeno de","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Ubirajara","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar M.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2017.10.009_bib0165","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0170","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1590\/S0037-86822012000500002","article-title":"Immunopathogenesis and neurological manifestations associated to HTLV-1 infection","volume":"45","author":"Souza","year":"2012","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.bjid.2017.10.009_bib0175","first-page":"78","article-title":"Neurological symptoms and disability in HTLV-1 associated myelopathy","volume":"23","author":"Carod-Artal","year":"2008","journal-title":"Neurologia"},{"key":"10.1016\/j.bjid.2017.10.009_bib0180","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1590\/S0037-86822010000600013","article-title":"HTLV-1 associated myelopathy: clinical and epidemiological profile in a 10-year case series study","volume":"43","author":"Champs","year":"2010","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.bjid.2017.10.009_bib0185","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.urology.2007.01.052","article-title":"Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers","volume":"69","author":"Castro","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.bjid.2017.10.009_bib0190","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1590\/S1677-5538.IBJU.2013.06.13","article-title":"Association between urinary symptoms and quality of life in HTLV-1 infected subjects without myelopathy","volume":"39","author":"Andrade","year":"2013","journal-title":"Int Braz J Urol: Off J Braz Soc Urol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0195","doi-asserted-by":"crossref","first-page":"e0128103","DOI":"10.1371\/journal.pone.0128103","article-title":"Psychiatric disorders in HTLV-1-infected individuals with bladder symptoms","volume":"10","author":"Orge","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bjid.2017.10.009_bib0200","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejogrb.2009.07.024","article-title":"Impact of HTLV-I in quality of life and urogynecologic parameters of women with urinary incontinence","volume":"147","author":"Diniz","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0205","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1590\/S1677-55382007000200016","article-title":"Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals","volume":"33","author":"Castro","year":"2007","journal-title":"Int Braz J Urol: Off J Braz Soc Urol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0210","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/nau.22395","article-title":"The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients","volume":"33","author":"Chen","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.bjid.2017.10.009_bib0220","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1590\/0037-8682-0029-2014","article-title":"The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy","volume":"47","author":"Carneiro Neto","year":"2014","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.bjid.2017.10.009_bib0225","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/nau.20737","article-title":"Reviewing the ICS 2002 terminology report: the ongoing debate","volume":"28","author":"Abrams","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.bjid.2017.10.009_bib0230","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2490-9-18","article-title":"Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence","volume":"9","author":"Campbell","year":"2009","journal-title":"BMC Urol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0235","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/nau.22512","article-title":"How to define a refractory idiopathic overactive bladder?","volume":"34","author":"Phe","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.bjid.2017.10.009_bib0240","article-title":"How to define a refractory idiopathic overactive bladder?","author":"Phe","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.bjid.2017.10.009_bib0245","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1089\/aid.2006.22.931","article-title":"Proposal for diagnostic criteria of tropical spastic paraparesis\/HTLV-I-associated myelopathy (TSP\/HAM)","volume":"22","author":"De Castro-Costa","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.bjid.2017.10.009_bib0250","first-page":"6649","article-title":"Intradetrusor onabotulinumtoxinA injection: how I do it","volume":"20","author":"Shenot","year":"2013","journal-title":"Can J Urol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0255","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1471-0528.1997.tb11006.x","article-title":"A new questionnaire to assess the quality of life of urinary incontinent women","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0260","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/nau.22671","article-title":"Measurement of post-void residual urine","volume":"35","author":"Asimakopoulos","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.bjid.2017.10.009_bib0265","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.urology.2009.11.041","article-title":"Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder","volume":"75","author":"Oliveira","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.bjid.2017.10.009_bib0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jns.2003.08.004","article-title":"Natural course of voiding function in patients with human T-cell lymphotrophic virus type 1-associated myelopathy","volume":"217","author":"Mori","year":"2004","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.bjid.2017.10.009_bib0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2334-7-15","article-title":"The cause of urinary symptoms among Human T Lymphotropic Virus Type I (HLTV-I) infected patients: a cross sectional study","volume":"7","author":"Rocha","year":"2007","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2017.10.009_bib0280","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/civ229","article-title":"Neurological manifestations in human T-cell lymphotropic virus type 1 (HTLV-1)-infected individuals without HTLV-1-associated myelopathy\/tropical spastic paraparesis: a longitudinal cohort study","volume":"61","author":"Tanajura","year":"2015","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.bjid.2017.10.009_bib0285","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00345-016-1862-y","article-title":"Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms","volume":"35","author":"Marcelissen","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0290","doi-asserted-by":"crossref","first-page":"e105989","DOI":"10.1371\/journal.pone.0105989","article-title":"Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder","volume":"9","author":"Jiang","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bjid.2017.10.009_bib0295","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/nau.22598","article-title":"The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis","volume":"34","author":"Cui","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.bjid.2017.10.009_bib0300","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.bjid.2017.10.009_bib0305","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.bjid.2017.10.009_bib0310","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/nau.23196","article-title":"Long-term compliance and results of intravesical botulinum toxin A injections in male patients","volume":"36","author":"Rahnama\u2019i","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.bjid.2017.10.009_bib0315","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/nau.22663","article-title":"Characterization of symptom bother and health-related quality of life in Japanese female patients with overactive bladder","volume":"34","author":"Gotoh","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.bjid.2017.10.009_bib0320","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.urology.2015.09.036","article-title":"Effects of physiotherapy in the treatment of neurogenic bladder in patients infected with human T-lymphotropic virus 1","volume":"89","author":"Andrade","year":"2016","journal-title":"Urology"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867017307055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867017307055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T01:21:33Z","timestamp":1535073693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867017307055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1413867017307055"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2017.10.009","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2017.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}